Research ArticleConference Proceedings

Clinical Pharmacology of Oral Maintenance Therapies for Obstructive Lung Diseases

Roy A Pleasants
Respiratory Care June 2018, 63 (6) 671-689; DOI: https://doi.org/10.4187/respcare.06068

References

  1. 1.↵
    1. Bateman ED,
    2. Izquierdo JL,
    3. Harnest U,
    4. et al
    . Efficacy and safety of roflumilast in the treatment of asthma. Ann Allergy Asthma Immunol 2006;96(5):679–668.
    OpenUrlCrossRefPubMedWeb of Science
  2. 2.↵
    Global Strategy for the Diagnosis, Management and Prevention of COPD web site. Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2018. Available at: http://goldcopd.org Accessed March 23, 2018.
  3. 3.↵
    1. Wedzicha JA,
    2. Calverley PMA,
    3. Albert RK,
    4. et al
    . Prevention of COPD exacerbations: a European Respiratory Society/American Thoracic Society guideline. Eur Respir J 2017;50(3):1602265.
    OpenUrlAbstract/FREE Full Text
  4. 4.↵
    1. Chong J,
    2. Leung B,
    3. Poole P
    . Phosphodiesterase inhibitors for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2017;19;9:CD002309.
    OpenUrl
  5. 5.↵
    Patient-Centered Outcomes Research Institute web site. Available at: https://www.pcori.org/research-results/2016/roflumilast-or-azithromycin-prevent-copd-exacerbations-reliance Accessed March 23, 2018.
  6. 6.↵
    1. Wedzicha JA,
    2. Calverley PMA,
    3. Rabe KF
    . Roflumilast: a review of its use in the treatment of COPD. Int J COPD 2016;11:81–90.
    OpenUrl
  7. 7.↵
    1. Hatzelmann A,
    2. Morcillo EJ,
    3. Lungralla G,
    4. et al
    . The pre-clinical pharmacology of roflumilast, a selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease. Pulm Pharmcol Ther 2010;23(4):235–256.
    OpenUrl
  8. 8.↵
    1. Grootendorst DC,
    2. Gauw SA,
    3. Verhoosel RM,
    4. et al
    . Reduction in sputum neutrophil and eosinophil numbers by the PDE4 inhibitor roflumilast in patients with COPD. Thorax 2007;62(12):1081–1087.
    OpenUrlAbstract/FREE Full Text
  9. 9.↵
    1. van Schalkwyk E,
    2. Strydom K,
    3. Williams Z,
    4. et al
    . Roflumilast, an oral, once-daily phosphodiesterase 4 inhibitor, attenuates allergen-induced asthmatic reactions. J Allergy Clin Immunol 2005;116(2):292–298.
    OpenUrlCrossRefPubMedWeb of Science
  10. 10.↵
    1. Kawamatawong T
    . Roles of roflumilast, a selective phosphodiesterase 4 inhibitor, in airway diseases. J Thorac Dis 2017;9:1144–1154.
    OpenUrl
  11. 11.↵
    1. Bethke TD,
    2. Lahu G
    . High absolute bioavailability of the new oral phosphodiesterase-4 inhibitor roflumilast. Int J Clin Pharmacol Therapeutics 2011;49:51–57.
    OpenUrl
  12. 12.↵
    1. Hauns B,
    2. Hermann R,
    3. Hunnemeyer A,
    4. et al
    . Investigation of a potential food effect on the pharmacokinetics of roflumilast, an oral, once-daily phosphodiesterase 4 inhibitor, in healthy subjects. J Clin Pharmacol 2006;46(10):1146–1153.
    OpenUrlCrossRefPubMedWeb of Science
  13. 13.↵
    1. Lahu G,
    2. Nassr N,
    3. Hunnemeyer A
    . Pharmacokinetic evaluation of roflumilast. Expert Opin Drug Metab Toxicol 2011;7(12):1577–1591.
    OpenUrlCrossRefPubMed
  14. 14.↵
    AstraZeneca Pharmaceuticals LP. Daliresp® (Roflumilast) package insert. Wilmington, DE.
  15. 15.↵
    1. Buenestado A,
    2. Grassin-Delyle S,
    3. Guitard F,
    4. et al
    . Roflumilast inhibits the release of cytokines and TNF-a from human lung macrophages stimulated with lipopolysaccharide. Br J Pharmacol 2012;165(6):1877–1890.
    OpenUrlPubMed
  16. 16.↵
    1. Rabe KF,
    2. Bateman ED,
    3. O'Donnell D,
    4. Witte S,
    5. Bredenbroker D,
    6. Bethke TD
    . Roflumilast: an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2005;366(9485):563–571.
    OpenUrlCrossRefPubMedWeb of Science
  17. 17.↵
    1. Lahu G,
    2. Hünnemeyer A,
    3. von Richter O,
    4. Hermann R,
    5. Herzog R,
    6. McCracken N,
    7. Zech K
    . Effect of single and repeated doses of ketoconazole on the pharmacokinetics of roflumilast and roflumilast N-oxide. J Clin Pharmacol 2008;48(11):1339–1349.
    OpenUrlCrossRefPubMedWeb of Science
  18. 18.↵
    1. Lahu G,
    2. Hünnemeyer A,
    3. Herzog R,
    4. McCracken N,
    5. Hermann R,
    6. Elmlinger M,
    7. Zech K
    . Effect of repeated doses of erythromycin on the pharmacokinetics of roflumilast and roflumilast N-oxide. Int J Clin Pharmacol Ther 2009;47(4):236–245.
    OpenUrlPubMedWeb of Science
  19. 19.↵
    1. Nassr N,
    2. Hünnemeyer A,
    3. Herzog R,
    4. et al
    . Effects of rifampicin on the pharmacokinetics of roflumilast and roflumilast N-oxide in healthy subjects. Br J Clin Pharmacol 2009;68(4):580–587.
    OpenUrlCrossRefPubMed
  20. 20.↵
    1. Mollmann J,
    2. Kahles F,
    3. Lebherz C,
    4. et al
    . The PDE4 inhibitor roflumilast reduces weight gain by increasing energy expenditure and leads to improved glucose metabolism. Diabetes Obes Metab 2017;19(4):496–508.
    OpenUrl
  21. 21.↵
  22. 22.↵
    1. Facius A,
    2. Bagul N,
    3. Gardiner P,
    4. Watz H
    . Pharmacokinetics of a 4 week up-titration of roflumilast in the OPTIMIZE study. Am J Respir Crit Care 2017;195:A1337.
    OpenUrl
  23. 23.↵
    Global Initiative for Asthma web site. Global Strategy for Asthma Management and Prevention. Available at: http://ginasthma.org Accessed March 23, 2018.
  24. 24.↵
    National Asthma Education and Prevention web site. Guidelines for the Diagnosis and Management of Asthma (EPR-3). Available at: https://www.nhlbi.nih.gov/health-pro/guidelines/current/asthma-guidelines/full-report Accessed October 1, 2017.
  25. 25.↵
    1. Ichinose M,
    2. Sugiura H,
    3. Nagase H,
    4. et al
    . Japanese guidelines for adult asthma 2017. Allergol Int 2017;66(2):163e189.
    OpenUrl
  26. 26.↵
    1. Barnes PJ
    . Theophylline: new perspectives for an old drug. Am J Respir Crit Care Med 2003;167(6):813–818.
    OpenUrlCrossRefPubMedWeb of Science
  27. 27.↵
    1. Barnes PJ
    . Theophylline. Pharmaceuticals 2010;3(3):725–747.
    OpenUrl
  28. 28.↵
    1. Cazzola M,
    2. Page OP,
    3. Calzetta L,
    4. Matera MG
    . Pharmacology and therapeutics of bronchodilators. Pharmacol Rev 2012;64(3):450–504.
    OpenUrlAbstract/FREE Full Text
  29. 29.↵
    1. Culpitt SV,
    2. de Matos C,
    3. Russell RE,
    4. Donnelly LE,
    5. Rogers DF,
    6. Barnes PJ
    . Effect of theophylline on induced sputum inflammatory indices and neutrophil chemotaxis in COPD. Am J Respir Crit Care Med 2002;165(10):1371–1376.
    OpenUrlCrossRefPubMedWeb of Science
  30. 30.↵
    1. Lim S,
    2. Tomita K,
    3. Carramori G,
    4. et al
    . Low-dose theophylline reduces eosinophilic inflammation but not exhaled nitric oxide in mild asthma. Am J Respir Crit Care Med 2001;164(3):273–276.
    OpenUrlCrossRefPubMedWeb of Science
  31. 31.↵
    1. Pauwels R,
    2. van Revterghem D,
    3. van der Straeten M,
    4. Johanesson N,
    5. Persson CGA
    . The effect of theophylline and enprophylline on allergen-induced bronchoconstriction. J Allergy Clin Immunol 1985;76(4):583–590.
    OpenUrlCrossRefPubMedWeb of Science
  32. 32.↵
    1. Ito K,
    2. Lim S,
    3. Caramori G,
    4. Cosio B,
    5. Chung KF,
    6. Adcock IM,
    7. Barnes PJ
    . A molecular mechanism of action of theophylline: induction of histone deacetylase activity to decrease inflammatory gene expression. Proc Natl Acad Sci USA 2002;99(13):8921–8926.
    OpenUrlAbstract/FREE Full Text
  33. 33.↵
    1. Ram FS,
    2. Jardin JR,
    3. Atallah A,
    4. et al
    . Efficacy of theophylline in people with stable chronic obstructive pulmonary disease: a systematic review and meta-analysis. Respir Med 2005;99(2):135–144.
    OpenUrlCrossRefPubMed
  34. 34.↵
    1. Sutton PP,
    2. Pavia D,
    3. Bateman JR,
    4. Clarke SW
    . The effect of oral aminophylline on lung mucociliary clearance in man. Chest 1981;80(6 Suppl):889–892.
    OpenUrlPubMed
  35. 35.↵
    1. Dubuis E,
    2. Wortley MA,
    3. Grace MS,
    4. Maher SA,
    5. Adcock JJ,
    6. Birrell MA,
    7. Belvisi MG
    . Theophylline inhibits the cough reflex through novel mechanism of action. J Aller Clin Immunol 2014;133(3):1388–1398.
    OpenUrl
  36. 36.↵
    1. Aubier M
    . Effect of theophylline on diaphragmatic muscle function. Chest 1987;92(1 Suppl):27S–31S.
    OpenUrl
  37. 37.↵
    Alembic. Theophylline® package insert. Bridgewater, NJ.
  38. 38.↵
    1. Hendeles L,
    2. Massanari M,
    3. Weinberger M
    . Update on the pharmacodynamics and pharmacokinetics of theophylline. Chest 1985;88(2 Supp):103S–111S.
    OpenUrlPubMed
  39. 39.↵
    1. Mitenko PA,
    2. Olgilvie RI
    . Rational intravenous doses of theophylline. N Engl J Med 1973;289(12):600–603.
    OpenUrlCrossRefPubMedWeb of Science
  40. 40.↵
    1. Levy G,
    2. Kosooko R
    . Pharmacokinetic analysis of the effect of theophylline on pulmonary function in school-age children. J Pediatr 1975;86(5):789–793.
    OpenUrlCrossRefPubMedWeb of Science
  41. 41.↵
    1. Chrystyn H,
    2. Mulley BA,
    3. Peake MD
    . Dose response relation to oral theophylline in severe chronic obstructive airway disease. BMJ 1988;297(6662):1506–1510.
    OpenUrlAbstract/FREE Full Text
  42. 42.↵
    1. Sullivan P,
    2. Bekir S,
    3. Jaffer Z,
    4. Page C,
    5. Jeffery P,
    6. Costello J
    . Anti-inflammatory effects of low-dose theophylline in atopic asthma. Lancet 1994;343(8904):1006–1008.
    OpenUrlCrossRefPubMedWeb of Science
  43. 43.↵
    1. Jonkman JH
    . Therapeutic consequences of drug interactions with theophylline pharmacokinetics. J Allergy Clin Immunol 1986(4 part 2);78:736–742.
    OpenUrlCrossRefPubMedWeb of Science
  44. 44.↵
    1. Kroon LA
    . Drug interactions with smoking. Am J Health-Sys Pharm 2007;64(18):1917–1921.
    OpenUrlAbstract/FREE Full Text
  45. 45.↵
    1. Cramer CL,
    2. Patterson A,
    3. Alchakaki A,
    4. Soubani AO
    . Immunomodulatory indications of azithromycin in respiratory disease: a concise review for the clinician. Postgrad Med 2017;129(5):493–499.
    OpenUrl
  46. 46.↵
    1. Saiman L,
    2. Marshall BC,
    3. Mayer-Hamblett N,
    4. et al
    . Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA 2003;290(13):1749–1745.
    OpenUrlCrossRefPubMedWeb of Science
  47. 47.↵
    1. Wales D,
    2. Woodhead M
    . The anti-inflammatory effects of macrolides Thorax 1999;54(Suppl 2):S58–S62.
  48. 48.↵
    1. Gottfried M,
    2. Jung R,
    3. Mesick CR,
    4. Rubinstein I,
    5. Garey KW,
    6. Rodvold KA,
    7. Danziger LH
    . Effects of six-week clarithromycin therapy in corticosteroid-dependent asthma: a randomized, double-blind, placebo-controlled pilot study. Curr Ther Res 2004;65(1):1–12.
    OpenUrlCrossRef
  49. 49.
    1. Brusselle GG,
    2. Vanderstichele C,
    3. Jordens P,
    4. et al
    . Azithromycin for prevention of exacerbations in severe asthma (AZISAST): a multicentre randomized double-blind placebo-controlled trial. Thorax 2013;68(4):322–329.
    OpenUrlAbstract/FREE Full Text
  50. 50.↵
    1. Gibson PG,
    2. Yang IA,
    3. Upham JW,
    4. et al
    . Effect of azithromycin on asthma exacerbations and quality of life in adults with persistent uncontrolled asthma (AMAZES): a randomised, double-blind, placebo-controlled trial. Lancet 2017;390(10995):659–668.
    OpenUrlCrossRef
  51. 51.↵
    1. Parnham ML,
    2. Haber VE,
    3. Giamarellos-Bourboulis EJ,
    4. Perletti G,
    5. Verleden GM,
    6. Vos R
    . Azithromycin: mechanisms of action and their relevance for clinical applications. Pharmacol Ther 2014;143(2):225–243.
    OpenUrlCrossRefPubMed
  52. 52.↵
    1. Tamaoki J
    . The effect of macrolides on inflammatory cells. Chest 2004;125(2 supp):41S–51S.
    OpenUrlCrossRefPubMedWeb of Science
  53. 53.↵
    1. Daenas C,
    2. Hatziefthimiou A,
    3. Gourgoulianis K,
    4. Molyvdas PA
    . Azithromycin has a direct relaxant effect on precontracted airway smooth muscle. Eur J Pharmacol 553(1-3):280–287.
  54. 54.↵
    1. Han MK,
    2. Tayob N,
    3. Murray S,
    4. et al
    . Predictors of chronic obstructive pulmonary disease exacerbation reduction in response to daily azithromycin therapy. Am J Respir Crit Care Med 2014;189(12):1503–1508.
    OpenUrlCrossRefPubMedWeb of Science
  55. 55.↵
    1. Albert RK,
    2. Connett J,
    3. Bailey WC,
    4. et al
    . Azithromycin for prevention of exacerbations of COPD. N Engl J Med 2011;365(8):689–698.
    OpenUrlCrossRefPubMedWeb of Science
  56. 56.↵
    1. Uzun S,
    2. Djamin RS,
    3. Kluytmans JA,
    4. et al
    . Azithromycin maintenance treatment in patients with frequent exacerbations of chronic obstructive pulmonary disease (COLUMBUS): a randomized, double-blind, placebo-controlled trial. Lancet Respir Med 2014;2(5):361–368.
    OpenUrl
  57. 57.↵
    Pfizer Laboratories. Zithromax® package insert. New York, NY.
  58. 58.↵
    1. Wedzicha J,
    2. Calverley PMA,
    3. Albert RK,
    4. et al
    . Prevention of COPD exacerbations: a European Respiratory Society/American Thoracic Society guideline. Eur Respir J 2017;50(3):1602265.
    OpenUrlAbstract/FREE Full Text
  59. 59.↵
    1. Berkhof FF,
    2. Hertog NE,
    3. Ulil SM,
    4. Kerstjens HA,
    5. van den Berg JW
    . Azithromycin and cough-specific health status in patients with chronic obstructive pulmonary disease and chronic cough: a randomised controlled trial. Respir Res 2013;14:125.
    OpenUrlCrossRefPubMed
  60. 60.↵
    1. Westphal JF
    . Macrolide-induced clinically relevant drug interactions with cytochrome P-450A (CYP) 3A4: an update focused on clarithromycin, azithromycin and dirithromycin. Br J Clin Pharmacol 2000;50(4):285–295.
    OpenUrlCrossRefPubMedWeb of Science
  61. 61.↵
    1. Bolhuis MS,
    2. Panday PN,
    3. Pranger AD,
    4. Kosterink JG,
    5. Alffenaar JW
    . Pharmacokinetic drug interactions of antimicrobial drugs: a systematic review on oxazolidinones, rifamycines, macrolides, fluoroquinolones, and beta-lactams. Pharmaceutics 2011;3(4):865–913.
    OpenUrlCrossRef
  62. 62.↵
    Abbott Laboratories. Clarithromycin package insert (Biaxin®), Chicago, IL.
  63. 63.↵
    1. Broad J,
    2. Sanger GJ
    . The antibiotic azithromycin is a motilin receptor agonist in human stomach: comparison with erythromycin. Br J Pharmacol 2013;168(8):1859–1867.
    OpenUrlCrossRefPubMedWeb of Science
  64. 64.↵
    1. Simpson JL,
    2. Powell H,
    3. Baines KJ,
    4. et al
    . The effect of azithromycin in adults with stable neutrophilic COPD: a double blind randomised, placebo controlled trial. PLoS ONE 2014;9(8):e105609.
    OpenUrlCrossRefPubMed
  65. 65.↵
    1. Uzun C,
    2. Koten M,
    3. Kemal M
    . Reversible ototoxic effect of azithromycin and clarithromycin on transiently evoked otoacoustic emissions in guinea pigs. J Laryngol Otol 2001;115(8):622–628.
    OpenUrlPubMedWeb of Science
  66. 66.↵
    1. Haverkamp W,
    2. Breithardt G,
    3. Camm AJ,
    4. et al
    . The potential for QT prolongation and pro-arrhythmia by non-anti-arrhythmic drugs: clinical and regulatory implications: report on a Policy Conference of the European Society of Cardiology. Cardiovasc Res 2000;47(2):219–233.
    OpenUrlCrossRefPubMedWeb of Science
  67. 67.↵
    Guidance for Industry E14, Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-antiarrhythmic Drugs. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research. October 2012. https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM073153.pdf Accessed March 23, 2018.
  68. 68.↵
    1. Owens RC,
    2. Nolin TD
    . Antimicrobial-associated QT interval prolongation: pointes of interest. Clin Infect Dis 2006;43(12):1603–1611.
    OpenUrlCrossRefPubMedWeb of Science
  69. 69.↵
    1. Ray WA,
    2. Murray KT,
    3. Hall K,
    4. Arbogast PG,
    5. Stein CM
    . Azithromycin and the risk of cardiovascular death. N Engl J Med 2012;366(20):1881–1890.
    OpenUrlCrossRefPubMedWeb of Science
  70. 70.↵
    U.S. Food and Drug Administration Drug Information. FDA drug safety communication: azithromycin (Zithromax or Zmax) and the risk of potentially fatal heart rhythms. http://www.fda.gov/Drugs/DrugSafety/ucm341822.htm Accessed October 1, 2017.
  71. 71.↵
    1. Mosholder AD,
    2. Mathew J,
    3. Alexander JJ,
    4. Smith H,
    5. Nambiar S
    . Cardiovascular risks with azithromycin and other antibacterial drugs. N Engl J Med 2013;368(18):1665–1668.
    OpenUrlCrossRefPubMedWeb of Science
  72. 72.↵
    1. Ohtani H,
    2. Taninaka C,
    3. Hanada E,
    4. Kotaki H,
    5. Sato H,
    6. Sawada Y,
    7. Iga T
    . Comparative pharmacodynamic analysis of Q-T interval prolongation induced by the macrolides clarithromycin, roxithromycin, and azithromycin in rats. Antimicrob Agents Chemother 2000;44(10):2630–2637.
    OpenUrlAbstract/FREE Full Text
  73. 73.
    1. Atli O,
    2. Ilgin S,
    3. Altuntas H,
    4. Burukoglu D
    . Evaluation of azithromycin induced cardiotoxicity in rats. Int J Clin Exp Med 2015;8(3):3681–3690.
    OpenUrl
  74. 74.↵
    1. Zhang M,
    2. Xie M,
    3. Li S,
    4. et al
    . Electrophysiologic studies on the risks and potential mechanism underlying the proarrhythmic nature of azithromycin. Cardiovascular Toxicol 2017;17(3):434–440.
    OpenUrl
  75. 75.
    1. Ohara H,
    2. Nakamura Y,
    3. Watanabe Y,
    4. et al
    . Azithromycin can prolong QT interval and suppress ventricular contraction, but will not induce Torsade de pointes. Cardiovasc Toxicol 2015;15(3):232–240.
    OpenUrl
  76. 76.↵
    1. Milberg P,
    2. Eckardt L,
    3. Bruns HR,
    4. et al
    . Divergent proarrhythmic potential of macrolide antibiotics despite similar QT prolongation: fast phase 3 repolarization prevents early after depolarizations and Torsade de pointes. J Pharmacol Expermental Ther 2002;303(1):218–225.
    OpenUrl
  77. 77.↵
    1. Hancox JC,
    2. Masnain M,
    3. WVR Vieweg,
    4. Breden EL
    . Azithromycin, cardiovascular risks, QTc interval prolongation, Torsade de pointes, and regulatory issues: a narrative review based on the study of case reports Ther Adv Infect Dis 2013;1(5):155–165.
    OpenUrlCrossRefPubMed
  78. 78.↵
    1. Raschi EPE,
    2. Koci A,
    3. Moretti U,
    4. et al
    . Macrolides and torsadogenic risk: Emerging issues from the FDA pharmacovigilance database. J Pharmacovigilance 2013;1(6):467–479.
    OpenUrl
  79. 79.↵
    1. Svanstrom H,
    2. Pasternak B,
    3. Hviid A
    . Use of azithromycin and death from cardiovascular causes. N Engl J Med 2013;368(18):1704–1712.
    OpenUrlCrossRefPubMedWeb of Science
  80. 80.↵
    1. Rao GA,
    2. Mann JR,
    3. Shoaibi A,
    4. et al
    . Azithromycin and levofloxacin use and increased risk of cardiac arrhythmia and death. Ann Fam Med 2014;12(2):121–127.
    OpenUrlAbstract/FREE Full Text
  81. 81.↵
    1. Trifirò G,
    2. de Ridder M,
    3. Sultana J,
    4. et al
    . Use of azithromycin and risk of ventricular arrhythmia. CMAJ 2017;189(15):E560–E568.
    OpenUrlAbstract/FREE Full Text
  82. 82.↵
    1. Mortensen EM,
    2. Halm EA,
    3. Pugh MJ,
    4. et al
    . Association of azithromycin with mortality and cardiovascular events among older patients hospitalized with pneumonia. JAMA 2014;311(21):2199–2208.
    OpenUrlCrossRefPubMedWeb of Science
  83. 83.↵
    1. Almalki ZS,
    2. Guo JJ
    . Cardiovascular events and safety outcomes associated with azithromycin therapy: a meta-analysis of randomized controlled trials. Am Health Drug Benefits 2014;7(6):318–328.
    OpenUrl
  84. 84.↵
    1. Montuschi P
    . Role of leukotrienes and leukotriene modifiers in asthma. Pharmaceuticals 2010;3(6):1792–1811.
    OpenUrl
  85. 85.↵
    1. Adachi M,
    2. Taniguchi H,
    3. Tohda Y,
    4. Sano Y,
    5. Ishine T,
    6. Smugar SS,
    7. Hisada S
    . The efficacy and tolerability of intravenous montelukast in acute asthma exacerbations in Japanese patients. J Asthma 2012;49(6):649–656.
    OpenUrlPubMed
  86. 86.↵
    1. Lee JH,
    2. Kim HJ,
    3. Kim YH
    . The effectiveness of anti-leukotriene agents in patients with COPD: a systematic review and meta-analysis. Lung 2015;193(4):477–486.
    OpenUrl
  87. 87.↵
    1. Horwitz RJ,
    2. McGill KA,
    3. Busse WW
    . The role of leukotriene modifiers in the treatment of asthma. Am J Respir Crit Care Med 1998;157(5 Part 1):1363–1371.
    OpenUrlPubMedWeb of Science
  88. 88.↵
    1. Drazen JM,
    2. Israel E,
    3. O-Byrne PM
    . Treatment of asthma with drugs modifying the leukotriene pathway. N Engl J Med 1999;340(6):197–206.
    OpenUrlCrossRefPubMedWeb of Science
  89. 89.↵
    1. Gao J,
    2. CAI Feng,
    3. Peng M,
    4. Ma Y,
    5. Wang B
    . Montelukast improves air trapping, not airway remodeling, in patients with moderate-to-severe asthma: a pilot study. Chin Med J 2013;126(12):2229–2234.
    OpenUrl
  90. 90.↵
    1. Stevenson DD,
    2. Szczeklik A
    . Clinical and pathologic perspectives on aspirin sensitivity and asthma. J Allergy Clin Immunol 2006;118(4):773–786.
    OpenUrlCrossRefPubMed
  91. 91.↵
    1. Miligkos M,
    2. Bannuru RR,
    3. Alkofide H,
    4. Kher SR,
    5. Schmid CH,
    6. Balk EM
    . Leukotriene-receptor antagonists versus placebo in the treatment of asthma in adults and adolescents: a systematic review and meta-analysis. Ann Intern Med 2015;163(10):756–767.
    OpenUrl
  92. 92.↵
    1. Chaufan BF,
    2. Jeyaraman MM,
    3. Mann S,
    4. Lys J,
    5. Abou-Setta AM,
    6. Zarychanski R,
    7. Ducharme FM
    . Addition of anti-leukotriene agents to inhaled corticosteroids for adults and adolescents with persistent asthma. Cochrane Database Syst Rev 2017;3:CD010347.
    OpenUrl
  93. 93.↵
    1. Virchow JC,
    2. Prasse A,
    3. Naya I,
    4. Summerton L,
    5. Harris A
    . Zafirlukast improves asthma control in patients receiving high-dose inhaled corticosteroids. Am J Respir Crit Care Med 2000;162(2 Part 1):578–585.
    OpenUrlCrossRefPubMedWeb of Science
  94. 94.↵
    1. Lipworth BJ
    . Leukotriene receptor antagonists. Lancet 1999;353(9221):57–62.
    OpenUrlCrossRefPubMedWeb of Science
  95. 95.↵
    Merck and Company. Singulair® package insert. Whitehouse NJ Jun 2016. Accessed Nov 10, 2017.
  96. 96.↵
    Accolate package insert. Astra Zeneca Pharmaceuticals, Wilmington, Delaware. Jul 2009. Accessed Nov 10, 2017.
  97. 97.↵
    Chiesi. Zileuton (Zyflo®) package insert. Cary, NC.
  98. 98.↵
    1. Altman LC,
    2. Munk Z,
    3. Seltzer J,
    4. et al
    . A placebo-controlled, dose-ranging study of montelukast, a cysteinyl leukotriene–receptor antagonist. J Aller Clin immunol 1998;102(1):150–155.
    OpenUrl
  99. 99.↵
    1. Schwartz HJ,
    2. Petty T,
    3. Duke LM,
    4. Swanson LJ,
    5. Lancaster JF
    . A randomized controlled clinical trial comparing zileuton and theophylline in moderate asthma. Arch Intern Med 1998;158(2):141–148.
    OpenUrlCrossRefPubMedWeb of Science
  100. 100.↵
    1. Calapai G,
    2. Casciaro M,
    3. Miroddi M,
    4. Calapai F,
    5. Navarra M,
    6. Gangemi S
    . Montelukast-Induced adverse drug reactions: A review of case reports in the literature. Pharmacology 2014;94(1-2):60–70.
    OpenUrl
  101. 101.↵
    1. Meindina G,
    2. Haarman MG,
    3. van Hunsel F,
    4. de Vries TW
    . Adverse drug reactions of montelukast in children and adults. Pharma Res Per 2017;5(5):e00341.
    OpenUrl
  102. 102.↵
    1. Ernst P,
    2. Ernst G
    . Neuropsychiatric effects of montelukast in children. Eur Respir J 2017;50:1701020.
    OpenUrlAbstract/FREE Full Text
  103. 103.↵
    1. Ali MM,
    2. O'Brien CE,
    3. Cleves MA,
    4. Martin BC
    . Exploring the possible association between montelukast and neuropsychiatric events among children with asthma: a matched nested case-control study. Pharmacoepidemiol Drug Saf 2015;24(4):435–445.
    OpenUrl
  104. 104.↵
    1. Richardson PS,
    2. Phipps RJ
    . The anatomy, physiology, pharmacology, and pathology of tracheobronchial mucus secretion and the use of expectorant drugs in human disease. Pharmacol Ther 1978;3(4):441–479.
    OpenUrlWeb of Science
  105. 105.↵
    1. Bolser DC
    . Cough suppressant and pharmacological protussive therapy. Chest 2006;129(1 Supp):238S–249S.
    OpenUrlCrossRefPubMedWeb of Science
  106. 106.↵
    1. Santus P,
    2. Corsico A,
    3. Solidoro P,
    4. Braido F,
    5. Di Marco F,
    6. Scichilone N
    . Oxidative stress and respiratory system: pharmacological and clinical reappraisal of N-acetylcysteine. COPD 2014;11(6):705–717.
    OpenUrl
  107. 107.↵
    1. Whipple J,
    2. Terraciano T,
    3. Hunt J,
    4. Shepard A,
    5. Guenin E
    . Guaifenesin and its role as a treatment in mucus hypersecretion associated with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2017;195:A5713.
    OpenUrl
  108. 108.↵
    1. Wanner A,
    2. Salathe M,
    3. O'Riordan TG
    . Mucociliary clearance in the airways. Am J Respir Crit Care Med 1996;154(6 part 1):1868–1902.
    OpenUrlCrossRefPubMedWeb of Science
  109. 109.↵
    1. Taube C,
    2. Holz O,
    3. Mucke M,
    4. et al
    . Airway response to inhaled hypertonic saline in patients with moderate to severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001;164(10 Part 1);1810–1815.
    OpenUrlPubMedWeb of Science
  110. 110.↵
    Genentech Halts Pulmozyme COPD Trial. 16 July 1995. The Pharma Letter. https://www.thepharmaletter.com/article/genentech-halts-pulmozyme-copd-trial Accessed March 23, 2018.
  111. 111.↵
    1. Thomson ML,
    2. Pavia D,
    3. McNicol MW
    . A preliminary study of the effect of guaiphenesin on mucociliary clearance in the human lung. Thorax 1973;28(7):742–747.
    OpenUrlAbstract/FREE Full Text
  112. 112.
    1. Kokkola K,
    2. Vaara J
    . Clinical evaluation of terbutaline and glyceryl guaiacolate in chronic obstructive lung disease. Curr Ther Res Clin Exp 1976;19(3):397–404.
    OpenUrlPubMed
  113. 113.↵
    1. Chodosh S
    . Glyceryl guaiacolate: a controlled laboratory and clinical study. Am Rev Respir Dis 1984;90(6):285–293.
    OpenUrl
  114. 114.↵
    1. Hirsch SR,
    2. Viemes PF,
    3. Kory RC
    . The expectorant effect of glycerol guaiacolate in patients with chronic bronchitis: a controlled in vitro and in vivo study. Chest 1973;63(1):9–14.
    OpenUrlCrossRefPubMedWeb of Science
  115. 115.↵
    1. Sisson JH,
    2. Yonkers AJ,
    3. Waldman RH
    . Effects of guaifenesin on nasal mucociliary clearance and ciliary beat frequency in healthy volunteers. Chest 1995;107(3):747–751.
    OpenUrlCrossRefPubMed
  116. 116.↵
    1. Bennett WD,
    2. Kala A,
    3. Duckworth H,
    4. et al
    . Effect of a single 1,200-mg dose of Mucinex® on mucociliary and cough clearance during an acute respiratory tract infection. Respir Med 2015;109(11):1476–1483.
    OpenUrl
  117. 117.↵
    1. Sanguinetti CM
    . N-acetylcysteine in COPD: why, how, and when? Multidisciplinary Respir Med 2016;11:8.
    OpenUrl
  118. 118.↵
    1. Decramer M,
    2. Rutten-van Mölken M,
    3. Dekhuijzen PN,
    4. et al
    . Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on N-acetylcysteine Cost-Utility Study, BRONCUS): a randomised placebo-controlled trial. Lancet 2005;365(9470):1552–1560.
    OpenUrlCrossRefPubMedWeb of Science
  119. 119.↵
    1. Tse HN,
    2. Raiteri L,
    3. Wong KY,
    4. et al
    . High-dose N-acetylcysteine in stable COPD: the 1-year, double-blind, randomized, placebo-controlled HIACE study. Chest 2013;144(1):106–118.
    OpenUrlCrossRefPubMed
  120. 120.↵
    1. Zheng JP,
    2. Kang J,
    3. Huang SG,
    4. et al
    . Effect of carbocisteine on acute exacerbation of chronic obstructive pulmonary disease (PEACE Study): a randomised placebo-controlled study. Lancet 2008;371(9629):2013–2018.
    OpenUrlCrossRefPubMedWeb of Science
  121. 121.↵
    1. Poole P,
    2. Black PN
    . Mucolytic agents for chronic bronchitis or chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2010;2:CD001287.
    OpenUrlPubMed
  122. 122.↵
    1. Vilson L,
    2. Owen JS
    . Pharmacokinetic studies in healthy subjects for the development of an extended-release tablet formulation of guaifenesin: a 505(b)(2) new drug application approval. Clin Pharmacol Drug Dev 2013;2(1):25–32.
    OpenUrl
  123. 123.↵
    1. Wagner DL,
    2. Patel VS
    . Steady-state human pharmacokinetics and bioavailability of guaifenesin and pseudoephedrine in a sustained-release tablet relative to immediate-release liquids. Int J Pharm 1995;114(3):171–176.
    OpenUrl
  124. 124.↵
    1. Sadowska AM,
    2. Verbraecken J,
    3. Darquennes K,
    4. WA
    . Pharmacokinetics; role of N-acetylcysteine in the management of COPD. Int J Chron Obstruct Pulmon Dis 2006;1(4):425–434.
    OpenUrlPubMed
  125. 125.↵
    1. Zuin R,
    2. Palamidese A,
    3. Negrin R,
    4. Catozzo L,
    5. Scarda A,
    6. Balbinot M
    . High dose N–acetylcysteine in patients with exacerbations of chronic obstructive pulmonary disease. Clin Drug Invest 2005;25(6):401–408.
    OpenUrl
  126. 126.↵
    1. Sayin VI,
    2. Ibrahim MX,
    3. Larsson E,
    4. Nilsson JA,
    5. Lindahl P,
    6. Bergo MO
    . Antioxidants accelerate lung cancer progression in mice. Sci Translat Med 2014;6(221)ra15.
    OpenUrl
Back to top

In this issue

 

Print
Download PDF
Article Alerts
Email Article
Citation Tools

Jump to section

Related Articles

Cited By...

Keywords